Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvants for human vaccines--current status, problems and future prospects

R K Gupta1, G R Siber

  • 1Massachusetts Public Health Biologic Laboratories, State Laboratory Institute, Boston 02130, USA.

Vaccine
|October 1, 1995
PubMed
Summary

Adjuvants enhance vaccine effectiveness by boosting immune responses, but toxicity remains a challenge. Research focuses on safer, novel adjuvants and delivery systems for improved vaccine development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2008
Same author

Evaluation of the indirect effects of a pneumococcal vaccine in a community-randomized study.

Journal of biopharmaceutical statistics·2006
Same author

Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants.

The Pediatric infectious disease journal·2001
Same author

Design of a group-randomized Streptococcus pneumoniae vaccine trial.

Controlled clinical trials·2001
Same author

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
Same author

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000

Area of Science:

  • Immunology and Vaccinology
  • Biotechnology and Pharmaceutical Sciences

Background:

  • Adjuvants are critical for enhancing immune responses to poor immunogens in modern vaccines, improving antigenicity and reducing production costs.
  • The development of purified, subunit, and synthetic vaccines necessitates the use of adjuvants to elicit robust and long-lasting immunity.
  • Adjuvants allow selective modulation of immune responses, crucial for combating intracellular pathogens like viruses, parasites, and bacteria.

Purpose of the Study:

  • To review the challenges and advancements in the development and application of adjuvants for human vaccines.
  • To highlight the ongoing research into novel adjuvant formulations and delivery systems to overcome toxicity and efficacy limitations.

Main Methods:

  • Review of current literature on adjuvant formulations, including traditional aluminum salts and novel candidates like muramyl dipeptide derivatives, lipid A, liposomes, QS21, MF-59, and ISCOMS.

Related Experiment Videos

  • Discussion of challenges in adjuvant development, such as toxicity, antigen specificity, standardization of assays, and animal model limitations.
  • Exploration of advanced delivery systems, including biodegradable polymer microspheres for controlled release and mucosal targeting, and protein-polysaccharide conjugates for enhanced immunogenicity.

    • Main Results:

    • Aluminum-based adjuvants (hydroxide and phosphate) remain common but have limitations.
    • Significant progress has been made in developing alternative adjuvants with improved safety and efficacy profiles.
    • Biodegradable microspheres and protein-polysaccharide conjugates show promise for targeted delivery, reduced dosage, and combination vaccines.

    Conclusions:

    • Adjuvant research is vital for advancing vaccine technology, particularly for subunit and synthetic vaccines.
    • Overcoming toxicity and ensuring broad applicability remain key challenges in human adjuvant development.
    • Novel adjuvants and advanced delivery systems offer promising avenues for creating more effective and safer vaccines.